VisiRose is a clinical-stage biotechnology company based in Knoxville, TN focused on developing Rose Bengal photodynamic antimicrobial therapy (RB PDAT) for infectious keratitis and other serious eye infections. Its lead investigational drug, PV-305, applies photodynamic therapy (PDAT) using Provectus’s bioactive synthetic small molecule, Rose Bengal Sodium (RBS). The company is leveraging new ocular RB PDAT research from the University of Miami’s Bascom Palmer Eye Institute and Ophthalmic Biophysics Center in collaboration with Provectus Biopharmaceuticals. In January 2025 VisiRose raised $3M in Seed funding, with backers undisclosed. The company intends to use the funds to complete a pre‑IND meeting with the U.S. FDA, submit an IND application for PV-305, and manufacture an initial clinical supply to enable clinical trial initiation. Dominic Rodrigues leads the company as CEO.

Total raised

$3M

Funding rounds

1

Latest round

Seed

Latest activity

Jan 2025